Head-To-Head Analysis: Stevanato Group (NYSE:STVN) and Evotec (NASDAQ:EVO)

Stevanato Group (NYSE:STVN) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Stevanato Group and Evotec, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1	1	4	1	2.71
Evotec	1	0	3	0	2.50

Evotec has a consensus price target of $7.00, suggesting a potential upside of 150.00%. Given Evotec’s higher possible upside, analysts clearly believe Evotec is more favorable than Stevanato Group.

Earnings & Valuation

This table compares Stevanato Group and Evotec”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.34 billion	3.75	$158.21 million	€0.59	28.16
Evotec	$891.97 million	1.12	-$117.12 million	N/A	N/A

Stevanato Group has higher revenue and earnings than Evotec.

Volatility and Risk

Stevanato Group has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500.

Profitability

This table compares Stevanato Group and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Evotec	-26.20%	-24.93%	-11.35%

Insider & Institutional Ownership

5.8% of Evotec shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Stevanato Group beats Evotec on 9 of the 12 factors compared between the two stocks.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.